Multiscale Metrology Suite for Next-Generation Health Nanotechnologies
Lead Research Organisation:
University of Strathclyde
Department Name: Inst of Pharmacy and Biomedical Sci
Abstract
The bespoke Multiscale Metrology Suite, will combine powerful leading-edge detectors for measuring nanomaterial properties and transform the measurement of health nanotechnologies. We will build a modular system combining the latest in flow field fractionation technologies with mass spectrometry, Raman and light scattering detectors for the physical and chemical measurement of nanomaterial properties.
The requested equipment will enable world-leading researchers at the University of Strathclyde, other UK academic institutions, and industry to accelerate their research into new technologies for healthcare applications and remain competitive in the global race for delivering new innovations in health. Moreover, this equipment will generate new research avenues and partnership opportunities that will create a step-change in the physical and chemical analytical capability and infrastructure for UK health nanotechnology research.
This leading-edge suite will ultimately reduce the time and costs associated with delivering new diagnostics and drug treatments, improving quality of life and delivering much needed lifesaving drugs to patients. Strong partnerships with industry partners and government facilities will ensure that this national facility will remain globally-competitive and deliver innovations.
The requested equipment will enable world-leading researchers at the University of Strathclyde, other UK academic institutions, and industry to accelerate their research into new technologies for healthcare applications and remain competitive in the global race for delivering new innovations in health. Moreover, this equipment will generate new research avenues and partnership opportunities that will create a step-change in the physical and chemical analytical capability and infrastructure for UK health nanotechnology research.
This leading-edge suite will ultimately reduce the time and costs associated with delivering new diagnostics and drug treatments, improving quality of life and delivering much needed lifesaving drugs to patients. Strong partnerships with industry partners and government facilities will ensure that this national facility will remain globally-competitive and deliver innovations.
Organisations
- University of Strathclyde (Collaboration, Lead Research Organisation)
- Astrazeneca (Collaboration)
- LGC LTD (Collaboration)
- University of Aberdeen (Collaboration)
- Malvern Panalytical (Collaboration)
- Medicines Discovery Catapult (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- Medicines Discovery Catapult (Project Partner)
- Centre for Process Innovation (Project Partner)
- LGC (Project Partner)
Publications
Abdullah MO
(2022)
Mitochondrial hyperfusion via metabolic sensing of regulatory amino acids.
in Cell reports
Abdulrahman R
(2025)
Frit-inlet asymmetric flow field-flow fractionation for the analysis of lipid nanoparticle-protein interactions
in Journal of Chromatography A
Al Sultan A
(2024)
Integrative analysis of toxicometabolomics and toxicoproteomics data: new molecular insights into thiazolidinedione-induced cardiotoxicity
in Metabolomics
Al Sultan A
(2024)
Toxicometabolomics-based cardiotoxicity evaluation of Thiazolidinedione exposure in human-derived cardiomyocytes.
in Metabolomics : Official journal of the Metabolomic Society
Alnoumas L
(2022)
Evaluation of the role of KPNA2 mutations in breast cancer prognosis using bioinformatics datasets.
in BMC cancer
Armstrong G
(2024)
Assessing the Manufacturability and Critical Quality Attribute Profiles of Anti-IL-8 Immunoglobulin G Mutant Variants
in Molecular Pharmaceutics
Armstrong G
(2024)
A First Insight into the Developability of an Immunoglobulin G3: A Combined Computational and Experimental Approach
in ACS Pharmacology & Translational Science
Armstrong GB
(2024)
A framework for the biophysical screening of antibody mutations targeting solvent-accessible hydrophobic and electrostatic patches for enhanced viscosity profiles.
in Computational and structural biotechnology journal
Armstrong GB
(2024)
Reconciling predicted and measured viscosity parameters in high concentration therapeutic antibody solutions.
in mAbs
Berardi D
(2022)
The Differential Metabolic Signature of Breast Cancer Cellular Response to Olaparib Treatment.
in Cancers
Cai Y
(2022)
Bile acid distributions, sex-specificity, and prognosis in colorectal cancer.
in Biology of sex differences
Cunningham MR
(2024)
Recounting the untold stories of breast cancer patient experiences: lessons learned from a patient-public involvement and engagement storytelling event.
in The International journal of pharmacy practice
Daramy K
(2024)
Nanoparticle Isolation from Biological Media for Protein Corona Analysis: The Impact of Incubation and Recovery Protocols on Nanoparticle Properties.
in Journal of pharmaceutical sciences
Daramy K
(2022)
Investigating the Impact of Shear Flow on Nanoparticle-Protein Interactions
in British Journal of Pharmacy
Daramy K
(2022)
The Application of Field-Flow Fractionation to the Analysis of Nanomedicines
in British Journal of Pharmacy
Davidson C
(2024)
The use of orthogonal analytical approaches to profile lipid nanoparticle physicochemical attributes
in Nano Futures
Kelly PE
(2022)
An Optimised Monophasic Faecal Extraction Method for LC-MS Analysis and Its Application in Gastrointestinal Disease.
in Metabolites
Malewicz NM
(2022)
Topical Capsaicin in Poly(lactic-co-glycolic)acid (PLGA) Nanoparticles Decreases Acute Itch and Heat Pain.
in International journal of molecular sciences
Roamcharern N
(2025)
Biomimetic Silk Nanoparticle Manufacture: Calcium Ion-Mediated Assembly.
in ACS biomaterials science & engineering
Van Den Driest L
(2024)
A gap analysis of UK biobank publications reveals SNPs associated with intrinsic subtypes of breast cancer.
in Computational and structural biotechnology journal
Van Den Driest L
(2022)
Development of an Accessible Gene Expression Bioinformatics Pipeline to Study Driver Mutations of Colorectal Cancer.
in Alternatives to laboratory animals : ATLA
Van Der Walle CF
(2022)
Report on Webinar Series Cell and Gene Therapy: From Concept to Clinical Use.
in Pharmaceutics
| Title | Project: "Nanoparticles and the Human Body" |
| Description | This is a podcast recording from my contribution to the European Crucible, and a discussion around challenges of interdisciplinary research in nanomedicine. Project: "Nanoparticles and the Human Body" Scotland - Netherlands - Czech Republic - France - Portugal Nanoparticles are of interest to many areas of physics, and can also be used as carriers for the safe and effective administration of drugs, or for theranostics (diagnostic and therapeutic capability in a single therapy) purposes, yet they can also interact with biological systems and lead to unwanted adverse effects. This objective of this project is to revolutionize the toolbox of analytical chemistry techniques in order to investigate nanoparticle interactions with the human body and its impact on medicine safety. The team expertise for this Societal Challenge is in Chemistry, Physics and Biomaterials: |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2025 |
| Impact | This podcast has been accessed by an audience of several thousand |
| URL | https://www.supa.ac.uk/opportunities/careers/european-crucible/nanoscience |
| Description | The generous funding from EPSRC has been instrumental in establishing a state-of-the-art facility dedicated to flow field flow fractionation (FFF) modalities. This facility has become a hub for innovation, fostering numerous collaborations with both academic and industrial partners across the UK. Our advanced capabilities have enabled groundbreaking research in novel nanomaterials for therapeutic applications. Notably, we have explored image-guided therapy using microbubbles for gastrointestinal cancers and partnered with the pharmaceutical sector to develop next-generation nanotechnology-based therapeutics. The facility has also contributed to driving our understanding of lipid chemistries and their impact on nanoparticle quality attributes and subsequent interactions with complex biological matrices. Additionally, our multiscale metrology suite has been pivotal in supporting this research. It has also played a crucial role in the training and development of over 25 early career researchers, equipping them with the skills and knowledge to become the next generation of leaders in this field. |
| Exploitation Route | We anticipate that the research outcomes from this facility will offer invaluable resources, pipelines, and infrastructure for academics, facilitating the transition of their research findings from the proof of concept stage to the development of new diagnostics or pharmaceutical products. Moreover, the industry sector will utilize this facility to advance capability development in new nanotechnology formulation areas and implement crucial analytical technologies essential for driving innovation. This collaborative effort will effectively address technical bottlenecks and challenges associated with improving the safety and efficacy of new nanotechnology-based therapeutics. Furthermore, beyond the original objectives, developers of analytical instrumentation will benefit from opportunities to integrate their equipment with the facility, thereby gaining greater recognition and visibility for their contributions to the field. |
| Sectors | Chemicals Healthcare Pharmaceuticals and Medical Biotechnology |
| Description | In January 2022, Dr. Rattray secured funding from the University of Strathclyde EPSRC Impact Acceleration Account to organize a public engagement event, featuring storytelling sessions with breast cancer patients. This initiative led to the creation of a workshop series aimed at fostering dialogue among breast cancer patients, researchers, and clinicians. Through collaborative discussions, perceptual barriers regarding the development of new drugs (nanomedicines) by researchers were identified, impacting patient care. Subsequently, these insights were utilized to develop educational resources and explore further patient engagement avenues to inform the public about ongoing research efforts through the facility. Overall, the impacts of this work will be changes in the provision of local NHS services for patient education and changes to initial pharmacy education on patient counselling on nanotechnology-based medicines. Since, further follow on funding has been secured to run additional patient engagement workshops, and hosting patients for placements in the research team. In January 2024, Dr Rattray was appointed to the laboratory of the government chemist as academic in residence. During this period, Dr Rattray has interacted with government scientists to initiate new collaborations, and her work in nanomedicine research led to invitation to present at the European Metrology for Health workshop in Jan 2025, and contribution to a consortium proposal for standardisation of analytics for nanomedicines as healthcare technologies. If successful with the proposal, the consortium will shape the analysis of nanomedicines in collaboration with regulators. The findings from this work are currently under preparation for publication, with the following preprint available https://www.medrxiv.org/content/10.1101/2023.06.19.23291192v1 |
| First Year Of Impact | 2022 |
| Sector | Healthcare,Pharmaceuticals and Medical Biotechnology |
| Impact Types | Cultural Policy & public services |
| Description | Appointment as Academic in Residence Laboratory of the Government Chemist |
| Geographic Reach | Europe |
| Policy Influence Type | Contribution to new or improved professional practice |
| Description | BBSRC Prosperity Partnership Award- Next-Gen ADC |
| Amount | £3,358,651 (GBP) |
| Funding ID | BB/Y003268/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2023 |
| End | 10/2028 |
| Description | EPSRC DTP studentship-Paul Considine |
| Amount | £72,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2023 |
| End | 04/2028 |
| Description | EPSRC DTP- Callum Davidson |
| Amount | £72,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2022 |
| End | 04/2026 |
| Description | EPSRC ICASE AstraZeneca |
| Amount | £120,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2024 |
| End | 10/2028 |
| Description | Investigating the impact of particle manufacturing process on nanomedicine biological fate |
| Amount | |
| Funding ID | 2430935 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 03/2024 |
| Description | Strathclyde-GSK Doctoral Training Programme |
| Amount | £88,000 (GBP) |
| Organisation | University of Strathclyde |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2023 |
| End | 04/2027 |
| Title | Development of a Raman flow cell |
| Description | In partnership with PostNova, the vendor of flow field flow fractionation, we develop a Raman flow cell that is otherwise not available on the market. This will allow simultaneous analysis of chemical signatures with Raman in combination with light scattering. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2024 |
| Provided To Others? | No |
| Impact | The impact of this tool will be to study changes in secondary and higher order structure of proteins and peptides, and how these are altered following interaction with nanocarriers as an example. It could also be applied to the separation and inline analysis of any Raman active substances. |
| Title | Biomimetic Silk Nanoparticle Manufacture: Calcium Ion-Mediated Assembly |
| Description | This dataset contains both raw and analysed data files, which are included as supplementary information in the manuscript. The files require GraphPad Prism and MestReNova software to open. Links to the required software are provided in the ReadMe file. This dataset accompanied a 2025 publication. https://pubs.acs.org/doi/full/10.1021/acsbiomaterials.4c02175 |
| Type Of Material | Database/Collection of data |
| Year Produced | 2025 |
| Provided To Others? | Yes |
| Impact | This dataset was published in 2025 with a manuscript. |
| URL | https://pureportal.strath.ac.uk/en/datasets/data-for-biomimetic-silk-nanoparticle-manufacture-calciu... |
| Title | Frit-Inlet Asymmetric Flow Field-Flow Fractionation for the Analysis of Lipid Nanoparticle-Protein Interactions |
| Description | This dataset contains data in excel file format which was created for the purpose of plotting figures within the paper and supplementary of "Frit-Inlet Asymmetric Flow Field-Flow Fractionation for the Analysis of Lipid Nanoparticle-Protein Interactions". |
| Type Of Material | Database/Collection of data |
| Year Produced | 2025 |
| Provided To Others? | Yes |
| Impact | Shared with published manuscript |
| URL | https://doi.org/10.15129/02457dcc-f32b-4528-900b-14dacd9c4e69 |
| Title | Using Orthogonal Analytical Approaches to Profile Lipid Nanoparticle Physicochemical Attributes |
| Description | Dataset accompanying nanofutures publication on orthogonal methods for lipid nanoparticle analysis |
| Type Of Material | Database/Collection of data |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| Impact | Dataset published accompanying a 2024 publication in Nano Futures- The use of orthogonal analytical approaches to profile lipid nanoparticle physicochemical attributes Davidson, C. G., Abdulrahman, R., Punnabhum, P., Cairns, M., Rattray, N. J. W., Capomaccio, R., Treacher, K., Perrie, Y. & Rattray, Z., 6 Sept 2024, In: Nano Futures. 8, 3, 16 p., 035001. |
| URL | https://doi.org/10.15129/0e076511-618a-45b3-ac43-96c61ed3e6ba |
| Description | Beta testing status with Malvern Panalytical |
| Organisation | Malvern Panalytical |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | I was approached by Malvern Panalytical to evaluate their latest nanoparticle tracking analysis equipment model within the facility. This would provide my laboratory with access to the leading technologies available prior to commercial release, as well as developing new leading protocols for the analysis of bionanomaterials. |
| Collaborator Contribution | Partners within this collaboration issued me with an instrument to be housed within my laboratory. |
| Impact | This collaborative activity is still ongoing and will continue to lead to the generation of SOPs, workflows and evaluation of the latest nanoparticle tracking analysis technologies. The collaboration is multi-sector and multidisciplinary in nature, as it relies on working with the industry sector, and those with a specialism in physics, engineering and instrument development. We successfully hosted the equipment from Malvern in October 2023, training >15 individual users and cross-validating the new platform technology against our existing analytical infrastructure in the multiscale metrology suite. |
| Start Year | 2023 |
| Description | Collaboration with AstraZeneca |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | I have been collaborating with AstraZeneca pharmaceuticals to develop their technical capability in the manufacture and analysis of lipid nanoparticles for oligonucleotide drug delivery, which was sparked from the award of funding for this national facility. This collaboration has led to funding being secured for a AstraZeneca funded PhD scholarship in 2022 to pursue research in this area. |
| Collaborator Contribution | Partners in this collaboration have been involved in the co-supervision of the studentship, providing opportunities for the student to receive secondment within the industry sector. They have also contributed to the strategic direction of associated research priorities and running of the national facility from an industry perspective. |
| Impact | This is a multidisciplinary project, working with chemists in chemical development, and analytical and formulation scientists based at AstraZeneca. Expected impacts from this project will be knowledge transfer and exchange, contributing to progression of the AstraZeneca drug development pipeline. Since the award of the studentship in 2022, there has been additional funding awarded from AstraZeneca, with an EPSRC iCASE studentship being awarded in December 2023 (starting October 2024). |
| Start Year | 2021 |
| Description | Collaboration with GSK |
| Organisation | GlaxoSmithKline (GSK) |
| Department | GlaxoSmithKline, Stevenage |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | I have been appointed as supervisor on five GSK PhD at work studentships, some of which require use of the facility. |
| Collaborator Contribution | The partner organization have an existing biopharmaceuticals agreement for PhD studentships with Strathclyde University. As a component of this agreement, some of the studentships have focused on engineering and optimizing next generation antibody-based therapeutics. An element of this work and existing plans have been based on use of the multiscale metrology suite. |
| Impact | 1) The first studentship which commenced in 2021, received an award for the best presentation at the annual RSC Joint Pharmaceutical Analysis Group awards. https://www.jpag.org/?p=news 2) We recently secured a BBSRC prosperity partnership award (BB/Y003268/1), which started in Nov 2023. This proposal will use the facility as analytical infrastructure to analyse antibody-drug conjugates. |
| Start Year | 2021 |
| Description | Collaboration with Helen Mulvana in Strathclyde Biomedical Engineering |
| Organisation | University of Strathclyde |
| Department | Department of Biomedical Engineering |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I was approached to contribute to a Cancer Research UK project considering the design of functionalized nano and micro bubbles for improving the resolution and contrast of ultrasound imaging for early detection of cancer. My team's contribution were to provide access to the facility and train the associated postdoctoral researcher on the use of equipment within the multiscale metrology suite, assist in sample preparation and method development for analysis of prototype materials, and perform these analyses for >10 sample types. |
| Collaborator Contribution | The collaborator paid for accessing the equipment and included our contributions in subsequent conference abstracts submissions (Optical and acoustic characterisation of multimodal contrast agents for colorectal cancer lymph node detection submitted to the European Molecular Imaging Meeting 2023- https://e-smi.eu/meetings/emim/emim-2023/). This brought a new and added dimension to the range of measurements conducted through the facility. |
| Impact | This collaboration is still within early stages of its delivery and will lead to publications of research findings. This is an interdisciplinary collaboration in which I am working with physicists and biomedical engineers to work on functionalized nano and micro bubbles for image-guided cancer diagnostics. To-date there have been two conference presentations of the findings from this work, with a publication under preparation. |
| Start Year | 2022 |
| Description | Collaboration with the Laboratory of Government Chemist |
| Organisation | LGC Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The LGC are partners on this national facility, and have been contributing to the broader promotion of the facility and its capabilities. |
| Collaborator Contribution | - Contribution to the advisory board - Contribution to NML centres - Contribution to the development of UKRI proposal bids |
| Impact | As of Jan 2024, the PI (Dr Rattray) has been appointed as Academic in Residence for the National Measurement Laboratory, valid for 3 years. This will be a multidisciplinary collaboration in developing new partnerships with the NML, industry and academia in the area of nanotechnology based metrology. |
| Start Year | 2021 |
| Description | Partnership with the Medicines Discovery Catapult |
| Organisation | Medicines Discovery Catapult |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | At the point of award of funding for this EPSRC facility, I was invited to give a talk on complex medicines and their bioanalysis. I gave a webinar in June 2021, which was recorded and subsequently key points were summarized in a report published by the medicines discovery catapult. |
| Collaborator Contribution | The MDC as partners are involved in the Strategic Advisory Board and governance of the multiscale metrology suite facility. |
| Impact | Please see above- contribution to the webinar on complex medicines and connectivity with other investigators within the UK ecosystem i.e. SEDA pharmaceutical development services and researchers at the University of Liverpool. |
| Start Year | 2021 |
| Description | University of Aberdeen- Platt research group |
| Organisation | University of Aberdeen |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The multiscale metrology suite was used to analyse samples provided by the Platt research team. |
| Collaborator Contribution | We collaborated on the analysis of exosomes derived from cell cultures. Our facility ran samples and provided guidance to the collaborator on the quality of processes used to prepare exosomes. |
| Impact | At present, this collaboration is during early stages and will continue through additional collaborations. The project is multidisciplinary, between the Aberdeen medical school and our facility where we are performing biophysical analysis of these samples. |
| Start Year | 2023 |
| Description | Academy of Pharmaceutical Sciences seminar |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | I presented a webinar ran by the academy of pharmaceutical sciences on the standardisation of nanomedicine analytics. The focus of this talk was discussing the process involved in developing an infrastructure proposal bid and the set up of such a facility. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.linkedin.com/feed/update/urn:li:activity:7077938499420606464/ |
| Description | Annual Aberdeen University Medical School Festive Lecture |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | This was a webinar to schools in Scotland, which involved showcasing the range of research activities underpinned by this EPSRC national facility. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fabdn.cloud.panopto.eu%2FPanopto%2F... |
| Description | BioPronet BEST Entrepreneurial workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | I was invited to deliver a masterclass on the analysis of oligonucleotides and their formulation to a group of postgraduate researchers and postdoctoral researchers selected nationally for this BBSRC workshop. I provided guidance to the students on the background and theory guiding the design and analysis of these molecules, which was used as background information to inform the design of a gene therapy product by the different teams. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Coverage of the facility in Nanotechnology World Association newsletter |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Website covering the news of the facility following the Strathclyde press release |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.nanotechnologyworld.org/othernews/strathclyde-to-establish-nanotechnologies-facility |
| Description | Magazine coverage of the facility |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Media coverage following the Strathclyde press release on the facility, leading to increased growth in interest |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.theengineer.co.uk/content/news/strathclyde-to-establish-nanotechnologies-facility |
| Description | Meet the Researcher 2023- Medical Research Scotland |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Presented a poster and handson activity about the drug development pipelines for nanomedicines and the science of measurement (the facility equipment) to secondary aged school pupils aged between 15-17 (>200 participants). A component of this was discussing associated disciplines and careers. 2 PhD candidates and 1 Research Technical Professional affiliated with the lab were involved in the delivery of these activities. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.myworldofwork.co.uk/marketplace/opportunities/2072-meet-the-researcher-showcase----thurs... |
| Description | National Physical Laboratory Celebrating Science |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | I presented on the multiscale metrology suites and ongoing activities on nanometrology to the national physical laboratory as part of their celebrating science seminar series. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.linkedin.com/posts/zahra-rattray-08365936_really-looking-forward-to-giving-this-talk-act... |
| Description | Patient group three part storytelling workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | The overall aim of the project was to promote dialogue and awareness between the stakeholders (patients, clinicians and scientists) involved in the care of patients diagnosed with breast cancer. The event was promoted on social media platforms (LinkedIn, Twitter and Facebook), and printed and sent to patients attending the NHS Lanarkshire clinic as an invitation letter. Both these routes for promoting the event were used to ensure that patients not traditionally targeted for public engagement events, would be invited to participate in this workshop series, addressing issues relating to regional disparities in public engagement activities. Workshop 1- An introduction to storytelling (Aug 2nd 2022, 5-8 pm) Workshop 2- Bringing your story to life (Aug 18th 2022, 10-3 pm) Workshop 3- Open mic evening (Sep 4th 2022, 4:30-7:30 pm) Across the three workshop sessions, >20 patient participants attended (6 patients attending all three sessions), and 6 scientist participants. This multidisciplinary project included co-creation of workshop formats to include the use of different aides (e.g. object memory and prompt cards) to develop patient narratives from their lived experiences. All scientist and clinician participants were involved and engaged in developing their own narratives and perspectives on breast cancer. Outputs from the workshop, following participant consent were captured and recorded in multiple media formats including audio recordings, digital images, digital artwork and hardcopy stories from patients, which will be used to produce legacy content for patients with breast cancer and the wider community. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.strath.ac.uk/whystrathclyde/news/2022/strathclyderesearcherstoraiseawarenessofbreastcanc... |
| Description | Patient group workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | This activity was a patient-public involvement and outreach event aimed at raising awareness of breast cancer research, and breaking down communication barriers between patients and scientists. The first round of these workshops took place in 2022, with further funding received from the NHS to continue with these workshops in minority ethnic and male patients. |
| Year(s) Of Engagement Activity | 2022,2024 |
| URL | https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fabdn.cloud.panopto.eu%2FPanopto%2F... |
| Description | Press release from Azo Nano |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The press release issued from Strathclyde was subsequently disseminated and shared through other online newsletters. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.azonano.com/news.aspx?newsID=38173 |
| Description | Press release on facility |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Press release on the award and development of the facility. This led to follow on interviews from sector organizations, which reported increased interest in the facility. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.strath.ac.uk/whystrathclyde/news/2021/uk-widefacilitytotestforfuturehealthnanotechnologi... |
| Description | RNA Therapies and Vaccines Conference Talk |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | I gave a talk on the facility and how it can be used to analyse the quality attributes of nanomedicines. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Scottish-EU crucible poster |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | I attended an event organised by the Scottish-EU crucible, which was focused on scientist involvement in policy engagement. I presented a poster on the facility and research it enables to politicians and practitioners. |
| Year(s) Of Engagement Activity | 2024 |